Sepsis Market Summary

• Sepsis is common, rising and time-critical. It is the end point of many infections, mainly lung infections and UTIs. Ageing populations and antimicrobial resistance keep adding to the burden. Survival depends mostly on how early it is recognized, so delays in diagnosis drive mortality.
• Diagnosis is the first bottleneck. There is no gold-standard test, and blood cultures are slow and unreliable. Treatment therefore often starts empirically, and many patients are identified only after organ damage has begun. Biomarker-based early detection are both a clinical need and a commercial opportunity.
• According to Centers for Disease Control and Prevention (CDC) (2026), ~1.7 million adults and more than 18,000 children develop sepsis annually in the US, highlighting the substantial clinical burden of sepsis across both adult and pediatric populations.
• Sepsis management relies on antibiotics, fluids, vasopressors and organ support, and no therapy that targets the underlying host response is approved. The most recent approval, TYZAVAN (2025), is labelled for septicemia, an infection-based indication rather than sepsis as a syndrome. This has little effect on clinical practice, because vancomycin is already standard for Gram-positive bacteremia and is widely used empirically in suspected sepsis. Its value lies in delivery: a ready-to-use, room-temperature-stable formulation that removes compounding and speeds administration in critical care, which may support uptake despite generic competition. This underscores the unmet need for novel agents beyond antibiotics.
• According to the European Sepsis Alliance, sepsis affects an estimated 3.4 million people in Europe each year, a burden reiterated by the European Society for Emergency Medicine (EUSEM) in 2025.
• Sepsis pipeline candidates are targeting mechanisms beyond pathogen killing. Adrenomed’s enibarcimab is a first-in-class, non-neutralizing anti-adrenomedullin antibody that protects vascular integrity. Clinical data support a biomarker-guided approach in early septic shock. Vivacelle Bio’s VBI-S is a phospholipid nanoparticle-based fluid therapy that redistributes nitric oxide to restore blood pressure in hypovolemic septic shock.
• According to the Japan Sepsis Alliance (JaSA) study group (2025), ~4.4 million hospitalized adults (≥18 years) were identified with sepsis in Japan between 2010 and 2020, based on the nationwide Diagnosis Procedure Combination (DPC) claims database.
• Sepsis is driven by a broad spectrum of bacterial pathogens, with both Gram-negative and Gram-positive organisms contributing substantially to the infectious burden, underscoring the heterogeneous microbial etiology of the condition.

DelveInsight’s “Sepsis Market Insights, Epidemiology, and Market Forecast – 2036” report delivers an in-depth understanding of sepsis, historical and forecasted epidemiology, as well as the sepsis market trends in the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan.

The Sepsis market report delivers a comprehensive analysis of the current treatment landscape, including standards of care, clinical practices, and evolving therapeutic algorithms. It evaluates, sepsis patient burden trends, revenue & market share dynamics, peak patient share & therapy uptake analysis, and provides an in-depth market size assessment and growth rate projections (Historical & Forecast 2022–2036) across the 7MM regions. The report highlights key unmet medical needs in sepsis and maps the competitive and clinical landscape to uncover high‑value opportunities, providing a clear outlook on future market growth potential. 

Sepsis Disease Understanding

Sepsis Overview

Sepsis is a serious, life-threatening condition that occurs when the body’s immune system overreacts to an infection, resulting in organ dysfunction. This exaggerated response damages the body’s own tissues and organs and, if not identified and treated quickly, can progress to shock, multiple organ failure, and even death. Almost any infection can lead to sepsis if untreated. Bacterial infections are the most common cause, but viral, fungal, and parasitic infections can also precipitate sepsis. Common infection sites include the appendix, abdomen, gallbladder, liver, intestines, brain, spinal cord, lungs, skin and soft tissue, and urinary tract. Sepsis itself is not contagious, but the infections that trigger it sometimes are.

Sepsis Diagnosis

Diagnosis of sepsis requires medical evaluation based on the combination of clinical signs and confirmatory investigations. Blood tests are used to check for infection and organ injury, cultures and other tests identify the causative germ, and imaging, such as X-rays or CT scans, may be performed to detect the source of infection or tissue damage.

Prevention is focused on reducing the risk of infection. This includes staying up to date with recommended vaccines such as the yearly influenza vaccine, practicing good hand hygiene, avoiding close contact with people who have infections that can spread, keeping cuts clean and covered until fully healed, and seeking prompt medical care for suspected infections.

Further details related to country-based variations are provided in the report...

Current Sepsis Treatment Landscape

Early recognition and prompt treatment are critical for improving outcomes in sepsis. Diagnosis involves identifying clinical warning signs, performing appropriate tests, and determining the underlying source of infection, followed by timely administration of targeted antimicrobial therapy against bacterial, fungal, parasitic, or viral pathogens. Supportive care includes intravenous fluids and, when required, vasopressors to manage hypotension and maintain adequate blood pressure. However, antimicrobial resistance remains a major challenge, potentially limiting treatment options and complicating infection control.

The FDA approved TYZAVAN for septicemia, reflecting its focus on pathogen-confirmed infections rather than broader syndromic categories such as sepsis. Although the label is narrower, clinical practice is unaffected, as vancomycin is already standard for Gram-positive bacteremia and is frequently used empirically in septic presentations. TYZAVAN’s ready-to-use, room-temperature stable formulation eliminates compounding steps and enables faster administration in critical care, providing a practical advantage that may support uptake despite generic competition.

Further details related to country-based variations are provided in the report...

Sepsis Epidemiology

The Sepsis epidemiology section of the sepsis market report offers information on the patient populations, including historical and projected trends for each of the seven major markets. Examining key opinion leader views from physicians or clinical experts can assist in identifying the reasons behind historical and projected trends. The diagnosed patient pool, their trends, and the underlying assumptions are all included in this section of the report.

This section also presents the data with relevant tables and graphs, offering a clear and concise view of the incidence of sepsis. Additionally, the report discloses the assumptions made during the analysis, ensuring data interpretation and presentation transparency. This epidemiological data is valuable for understanding the disease burden and its impact on the patient population across various regions.

Key Findings from Sepsis Epidemiological Analysis and Forecast

• As per DelveInsight analysis, the incident cases of sepsis in the US were ~2.4 million in 2025. The incidence of sepsis in the US is rising, driven by an aging population, higher incidence of comorbidities, and infections originating from the lungs, urinary tract, gut, skin, and bloodstream.
• In 2025, lung infections represented the largest source of sepsis cases in the US, accounting for approximately 35% of cases, followed by urinary tract infections (UTIs) at 25%, while gut and skin infections each accounted for 10%, and bloodstream infections represented 5%.
• In 2025, males accounted for approximately 52% of sepsis cases in the US, while females comprised around 48%. Sepsis cases in the US were almost evenly distributed between males and females, indicating that the condition poses a comparable risk to both genders and reinforcing the importance of universal approaches to prevention and management.
• According to International Society for Pharmacoeconomics and Outcomes Research (ISPOR) (2024), about 550,730 sepsis cases occur annually across five European countries, with the highest numbers in Germany (~147,401) and the UK (~144,792), followed by France (~105,016), Spain (~77,496), and Italy (~76,033).
• In 2025, sepsis without organ dysfunction accounted for the highest number of cases in the US, at approximately 1.4 million followed by septic shock and severe sepsis. Sepsis without organ dysfunction represented the majority of cases in the US, while severe sepsis and septic shock comprised a considerably smaller proportion.
• According to Tonai et al. (2022), ~516,000 adult sepsis patients were admitted to critical care units in Japan between April 2010 and March 2020, based on the nationwide DPC claims database. Of these, 90% had community-onset sepsis and 10% hospital-onset sepsis.
• According to European Sepsis Alliance (2017) affects people across all age groups in Europe, with approximately 75% of the estimated ~2.8 million survivors experiencing long-term sequelae, highlighting the substantial and persistent burden of the condition.
• As per Kobayashi et al. (2025) analyzed the nationwide DPC claims database for Japanese critical care units (FY2010–2019). Of ~1.88 million critical care patients with an infection-related diagnosis, ~512,000 (27%) met the sepsis criteria. Respiratory infections were the most common source of sepsis across all age groups, ranging from ~37% in patients aged 40–49 years to ~51% in those aged ≥90 years. 

Sepsis Epidemiology Segmentation

• Incident Cases of Sepsis
• Origin-specific Cases of Sepsis
• Gender-specific Cases of Sepsis
• Severity-specific Cases of Sepsis
• Total Treated Cases of Sepsis
• Refractory Cases of Sepsis

Sepsis Drug Analysis & Competitive Landscape

The sepsis drug chapter provides a detailed, market-focused review of approved therapies and the emerging pipeline across Phase II-III Sepsis clinical trials. It covers mechanism of action, clinical trial data, regulatory approvals, patents, collaborations, strategic partnerships upcoming key catalyst for each therapy, along with their advantages, limitations, and recent developments. This section offers critical insights into the sepsis treatment landscape, supporting market assessment, competitive analysis, and growth forecasting for the sepsis therapeutics market.

Approved Therapies for Sepsis

TYZAVAN (vancomycin): Hikma Pharmaceuticals

TYZAVAN (Vancomycin Injection) is a glycopeptide antibacterial indicated for the treatment of septicemia, infective endocarditis, skin and skin structure infections, bone infections, and lower respiratory tract infections in adult and pediatric patients (1 month and older) for whom appropriate dosing with this formulation can be achieved.

• In July 2025, Hikma Pharmaceuticals announced US FDA approval of TYZAVAN, a first-of-its-kind, ready-to-infuse formulation of vancomycin.

Note: Detailed marketed therapies assessment will be provided in the final report…

Sepsis Pipeline Analysis

Enibarcimab: AdrenoMed

Enibarcimab (formerly Adrecizumab) is a humanized, non-neutralizing monoclonal antibody directed against adrenomedullin (ADM), a key mediator of vascular integrity. By binding to ADM, it elevates circulating levels of bioactive ADM, thereby strengthening endothelial function and mitigating sepsis-related vascular leakage.

In May 2026, Adrenomed announced that the US Food and Drug Administration (FDA) and European Medicines Agency (EMA) had endorsed a single pivotal, biomarker-guided Phase III registration study of enibarcimab in septic shock. Patients will be selected using the bio-ADM and DPP3 biomarkers, and 28-day all-cause mortality will be the primary endpoint. The trial will begin once funding is secured. Adrenomed cited the 2026 Surviving Sepsis Campaign guidelines and the proposed US SEPSIS Act as signs of growing priority for personalized sepsis therapies.

Note: Detailed emerging therapies assessment will be provided in the final report...

Sepsis Market Outlook

The sepsis therapeutics market is further expected to increase by the major drivers, such as the rising incidence population, technological advancements, and upcoming therapies in the forecast period (2026–2036).

With ongoing research and continued dedication, the future holds hope for effective treatments and, ultimately, a cure for this challenging condition. According to DelveInsight, the sepsis market in the 7MM is expected to change significantly during the forecast period 2026-2036.

Sepsis Market Insights

DelveInsight’s ‘Sepsis Market Insights, Epidemiology, and Market Forecast – 2036’ report provides a detailed outlook of the current and future sepsis market, segmented within countries, by therapies, and by classes. Further, the market of each region is then segmented by each therapy to provide a detailed view of the current and future market share of all therapies.

Sepsis Market Size by Countries

The sepsis market size is assessed separately for various countries, including the US, EU4 (Germany, France, Italy, and Spain), the UK, and Japan. In 2025, the US held a significant share of the overall 7MM (Seven Major Markets) sepsis market, primarily attributed to the country’s higher incidence of the condition and the elevated cost of the available treatments. This dominance is projected to persist, especially with the potential early introduction of new products.

Sepsis Market Size by Therapies

Sepsis market size by therapies is categorized into current and emerging markets for the study period 2022–2036.

Note: Detailed market segment assessment will be provided in the final report...

Sepsis Drug Uptake

This section focuses on the sales uptake of potential of sepsis drugs that have recently been launched or are anticipated to be launched in the sepsis market between 2022 and 2036. It estimates the market penetration of sepsis drugs for a given country, examining their impact within and across classes and segments. It also touches upon the financial and regulatory decisions contributing to the probability of success (PoS) of the drugs in the sepsis market.

The emerging sepsis therapies are analyzed based on various attributes such as safety and efficacy in randomized clinical trials, order of entry and other market dynamics, and the unmet need they fulfil in the sepsis market.

Note: Detailed assessment of drug uptake and attribute analysis will be provided in the full report on sepsis...

Sepsis Market Access and Reimbursement

DelveInsight’s ‘Sepsis – Market Insights, Epidemiology, and Market Forecast – 2036’ report provides a descriptive overview of the market access and reimbursement scenario of sepsis.

This section includes a detailed analysis of the country-wise healthcare system for each therapy, enlightening the market access, reimbursement policies, and health technology assessments.

Sepsis Market Report Key Opinion Leaders (KOLs) Views

To keep up with current sepsis market trends and fill gaps in secondary findings, we interview KOLs and SMEs’ working in the sepsis domain. Their opinion helps understand and validate current and emerging therapies and treatment patterns or sepsis market trends. This will support the clients in potential upcoming novel treatments by identifying the overall scenario of the market and the sepsis unmet needs.

Sepsis KOL Insights

DelveInsight’s analysts connected with 50+ KOLs to gather insights; however, interviews were conducted with 15+ KOLs in the 7MM. These KOLs were from organizations, institutes, and hospitals, such as Duke University School of Medicine, University of Florida Gainesville, Stanford University, Hospital Clinic of Barcelona, Iwate Medical University, Leipzig University Hospital, University of Florida Gainesville, Florida, Service des Maladies de l'Appareil digestif, Hôpital Huriez, CHU, Lille, France,Hospital Clinic of Barcelona, Barcelona, Spain, Department of Internal Medicine, Iwate Medical University, Morioka, among others.

Note: Detailed assessment of KOL Views will be provided in the full report on sepsis....

Sepsis Competitive Intelligence Analysis

We conduct a competitive and market intelligence analysis of the sepsis market, utilizing various Competitive Intelligence tools such as SWOT analysis and market entry strategies. The inclusion of these analyses is contingent upon data availability, ensuring a comprehensive and well-informed assessment of the market landscape and competitive dynamics.

Sepsis Pipeline Development Activities

The Sepsis pipeline report offers an analysis of therapeutic candidates in Phase II and III stages and examines companies involved in developing targeted therapeutics for sepsis. It provides valuable insights into the advancements and progress of potential treatments in clinical development for this condition.

Sepsis Clinical Trials Activities

The Sepsis clinical trial analysis report covers information on collaborations, acquisition and merger, licensing, patent details, and other information for emerging sepsis therapies.

Sepsis Market Report Insights

• Sepsis Patient Population
• Sepsis Therapeutic Approaches
• Sepsis Pipeline Analysis
• Sepsis Market Size and Trends
• Sepsis Market Opportunities
• Impact of Upcoming Sepsis Therapies

Sepsis Market Report Key Strengths

• 11 Years Forecast
• The 7MM Coverage
• Sepsis Epidemiology Segmentation
• Key Cross Competition
• Highly Analyzed Sepsis Market
• Sepsis Drugs Uptake

Sepsis Market Report Assessment

• Sepsis Current Treatment Practices
• Sepsis Unmet Needs
• Sepsis Pipeline Product Profiles
• Sepsis Market Attractiveness
• Sepsis Market Drivers
• Sepsis Market Barriers

Key Questions Answered in the Sepsis Market Report:

• How common is sepsis?
• What are the key findings of sepsis epidemiology across the 7MM, and which country will have the highest number of patients during the study period (2022–2036)?
• What are the currently available treatments for sepsis?
• What are the disease risk, burden, and unmet needs of sepsis?
• At what CAGR is the sepsis market and its epidemiology is expected to grow in the 7MM during the forecast period (2026–2036)?
• How would the unmet needs impact the sepsis market dynamics and subsequently influence the analysis of the related trends?
• What would be the forecasted patient pool of sepsis in the 7MM covering the United States, EU4 (Germany, France, Italy, and Spain), the UK, and Japan?
• Among EU4 and the UK, which country will have the highest number of patients during the forecast period (2026–2036)?
• How many companies are currently developing therapies for the treatment of sepsis?

Reasons to buy Sepsis Market Forecast Report

• The report will help in developing business strategies by understanding the latest trends and changing treatment dynamics driving the sepsis market.
• Insights on patient burden/disease incidence, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
• To understand the existing market opportunity in varying geographies and the growth potential over the coming years.
• Distribution of historical and current patient share based on real-world prescription data along with reported sales of current treatment in the US, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan.
• Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors.
• Detailed analysis and ranking of class-wise potential current and emerging therapies under the attribute analysis section to provide visibility around leading classes.
• Highlights of access and reimbursement policies of approved therapies, barriers to accessibility of off-label expensive therapies, and patient assistance programs.
• To understand the perspective of key opinion leaders around the accessibility, acceptability, and compliance-related challenges of existing treatment to overcome barriers in the future.
• Detailed insights on the unmet needs of the existing market so that the upcoming players can strengthen their development and launch strategy.

Frequently Asked Questions

1. What are the treatment goals for sepsis?

The goals of sepsis treatment are to eliminate the infection, restore tissue perfusion, and prevent or limit organ dysfunction, thereby reducing mortality and long-term complications. This is achieved through early broad-spectrum antimicrobial therapy with source control, fluid resuscitation and vasopressors to maintain a mean arterial pressure of at least 65 mmHg, and organ support (such as ventilation or renal replacement therapy) as needed, with corticosteroids considered in septic shock that does not respond to vasopressors.

2. What are the challenges in managing sepsis?

Managing sepsis is difficult because it is hard to recognize early and to treat precisely. Symptoms are nonspecific and overlap with other conditions, particularly in older adults, who may present with confusion rather than fever, and no single diagnostic test exists. Blood cultures are slow and often negative, so clinicians must start empiric broad-spectrum antibiotics before the pathogen is known, which contributes to antimicrobial resistance. Outcomes depend heavily on how quickly treatment starts, since each hour of delay in septic shock is associated with higher mortality. Sepsis is also a heterogeneous syndrome, with variable sources, pathogens, and host responses, which is why many immunomodulatory trials have failed and why no targeted therapy is approved. Survivors often face long-term physical, cognitive, and psychological sequelae, readmissions, and the need for post-discharge care. Added to this are resource constraints in low- and middle-income settings and inconsistent adherence to guideline-based care bundles.

3. What are the key factors driving the growth of the Sepsis market?

The growth of the sepsis market is driven mainly by rising incidence, an aging population, and persistent unmet need. Sepsis cases are increasing as the elderly population grows and as more people live with chronic conditions such as diabetes, cancer, and kidney disease, and as more patients undergo surgery, invasive procedures, or immunosuppressive treatment. Rising antimicrobial resistance is raising demand for new antibiotics and alternative therapies, while the lack of an approved targeted therapy has encouraged investment in novel candidates such as biomarker-guided and immunomodulatory agents. Greater clinical awareness, updated guidelines such as the Surviving Sepsis Campaign, and government initiatives that push for early recognition and treatment are expanding diagnosis and hospital protocols.

4. How will the Sepsis Market and Epidemiology Forecast Report benefit clients?

The sepsis market and epidemiology forecast report helps clients make informed strategic and investment decisions by providing a clear view of the current and future sepsis landscape across the 7MM (US, Germany, France, Italy, Spain, UK, and Japan). Epidemiology forecasts, covering incidence and segmentation by age, sex, and onset type, help clients size the treatable patient population and plan for demand. The market analysis outlines current treatment practices, guideline recommendations, and unmet needs, which helps identify gaps where new therapies could succeed. Pipeline and competitive intelligence on emerging candidates, their stage of development, and their mechanisms allow clients to benchmark assets, spot partnership or licensing opportunities, and anticipate future competition. Market forecasts and uptake assumptions support revenue planning, portfolio prioritization, and go-to-market strategy, while insight into regulatory and reimbursement trends helps clients reduce risk and time development and launch more effectively.